ImmuCell Corporation — Q1 2014 Form 10-Q
Business context and reporting period. ImmuCell develops, manufactures and sells animal-health products for the dairy and beef industries, including First Defense, Wipe Out Dairy Wipes and California Mastitis Test. The unaudited quarter ended March 31, 2014; comparisons are with the three months ended March 31, 2013 unless noted.
Financial performance and position
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Product sales | $2.082 million | $1.847 million; up 13% |
| Gross margin | $1.150 million; 55% of sales | $1.054 million; 57% of sales |
| Operating income | $13,000 | $327,000 |
| Income before taxes | $1,000 | $371,000 |
| Net income (loss) | $(13,000), or less than $(0.01) per share | $204,000, or $0.07 per diluted share |
| Operating cash flow | $305,000 | $445,000 |
| Cash and cash equivalents | $2.240 million | $2.270 million at December 31, 2013 |
| Cash, cash equivalents and investments | $5.472 million | $5.255 million at December 31, 2013 |
| Bank debt | $1.040 million | $1.087 million at December 31, 2013 |
Operating cash flow was positive, but declined year over year. Cash decreased by $31,000 during the quarter; investing activities used $292,000, including a $496,000 purchase of long-term investments, while financing activities used $44,000, primarily for debt repayments. Capital expenditures were $45,000 in cash payments; the filing also reports $192,000 of capital expenditures included in accounts payable. Net working capital was approximately $5.969 million, down $663,000 from year-end. Total assets were $11.116 million and stockholders’ equity was $9.392 million at March 31. The $500,000 revolving credit line was unused, and the company reported compliance with its debt covenants. The mortgage rate was hedged at a fixed 6.04%.
Material changes and operating drivers
- Sales rose 13%; management said approximately $155,000 of orders could not be shipped before quarter-end because of pending regulatory lot releases. It estimated sales growth would have been 21% if all first-quarter orders had shipped.
- First Defense sales increased 7%, while Wipe Out Dairy Wipes sales declined 13%. Pet wipes sales increased 219%, contributing to 37% growth in the overall topical-wipes product line. California Mastitis Test sales increased 11%.
- Gross margin dollars increased 9%, but the margin rate fell to 55% from 57%. Management cited product mix and manufacturing costs; it noted production had been reduced in the second half of 2013 for equipment upgrades and that inventory was being rebuilt.
- Product development expense increased 123% to $594,000. Approximately $412,000 related to modifications and equipment for in-house pharmaceutical-grade Nisin production for the Mast Out program. Sales and marketing expense increased 29% to $285,000; administrative expense increased 8% to $258,000.
- Q1 2013 other income included an approximately $62,000 insurance demutualization payment. This, along with the higher 2014 development spending, contributed to the sharp decline in reported earnings.
Outlook, risks and contingencies
- Management expected a larger loss in Q2 and a loss for full-year 2014, despite projecting a return to breakeven or profitability in the second half. It expected 2014 gross margin to remain near current levels and targeted a full-year margin above 50%.
- The company approved approximately $1.5 million for equipment and facility modifications to produce pharmaceutical-grade Nisin. Most of the remaining project investment was expected to be expensed in Q2. Separately, it was planning a facility addition and related production equipment budgeted at approximately $1.5 million, with use targeted for Q4 2014. The filing also reports approximately $379,000 of contracts and purchase orders related to the Nisin project.
- Mast Out requires FDA approval before U.S. commercial sales. The company targeted an initial CMC Technical Section submission for late 2014 or early 2015; it said approval and test marketing might be possible by the end of 2015, but could be delayed into 2016. The HFS Technical Section completion was then expected in 2015. Timing and approval are uncertain.
- Management said larger-scale Nisin production would require further investment and that available funding or a commercial partner was uncertain. A previous prospective partner did not proceed. The company was pursuing regulatory progress and limited-scale production independently while retaining other financing and partnering options.
- Key business risks include reliance on First Defense, concentration in two distributors (61% of Q1 sales and 66% of trade receivables), dairy and beef industry economics, competition, regulatory and manufacturing execution, raw-material and facility dependencies, and the need for financing to scale Mast Out. The filing says the FDA’s 2013 routine facility inspection resulted in a favorable report with only minor observations.
- Management reported effective disclosure controls and no material quarterly change in internal controls. The filing reported no legal proceedings. The Common Stock Rights Plan was stated to expire September 19, 2014.
Important facts for investors to verify
- Whether the deferred $155,000 of orders shipped and whether inventory and production returned to targeted levels after the reported delays.
- Actual spending, timing and funding for the Nisin production project and the planned facility expansion; the filing describes both significant investment needs.
- FDA review progress and the status of HFS and CMC submissions, including any change to Mast Out approval and commercialization estimates.
- Whether sales growth, margins and operating cash flow support management’s expected second-half recovery and the targeted full-year gross margin above 50%.
- Ongoing distributor concentration, customer receivable exposure, and the status or expiration of the Rights Plan.